Mosby's 2014 Nursing Drug Reference (367 page)

BOOK: Mosby's 2014 Nursing Drug Reference
9.94Mb size Format: txt, pdf, ePub
sildenafil (Rx)

(sil-den′a-fill)

Revatio, Viagra

Func. class.:
Erectile agent, antihypertensive, peripheral vasodilator

Chem. class.:
Phosphodiesterase type-5 inhibitor

Do not confuse:
Viagra
/Allegra

ACTION:

Enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5), which is necessary for degrading cGMP in the corpus cavernosum

USES:

Treatment of erectile dysfunction, improvement in exercise ability, pulmonary hypertension

Unlabeled uses:
Sexual dysfunction (women); lower urinary tract symptoms and erectile dysfunction (with alfuzosin); altitude sickness, Raynaud’s disease

CONTRAINDICATIONS:

Hypersensitivity to this product or nitrates

Precautions:
Pregnancy (B), anatomical penile deformities, sickle cell anemia, leukemia, multiple myeloma, retinitis pigmentosa, bleeding disorders, active peptic ulceration, CV/renal/hepatic disease, multiproduct antihypertensive regimens, geriatric patients

DOSAGE AND ROUTES
Calculator
Erectile dysfunction (Viagra only)

• Adult male <65 yr:
PO
50 mg 1 hr before sexual activity; may be increased to 100 mg or decreased to 25 mg; max 1×/day

• Adult ≥65 yr (male):
PO
25 mg as needed about 1 hr before sexual activity

Renal/hepatic dose

• Adult:
PO
(Child-Pugh A, B) 25 mg, take 1 hr before sexual activity; max 1×/day; CCr <30 ml/min, 25 mg starting dose

Pulmonary hypertension (Revatio only)

• Adult:
PO
20 mg tid; take 4-6 hr apart;
IV BOL
10 mg tid

Pulmonary hypertension induced by altitude sickness (unlabeled)

• Adult:
PO
40 mg 6-8 hr after arriving at 14,272 ft, then 40 mg tid × 6 days

Anorgasmy in antidepressant therapy/sexual dysfunction in women (unlabeled)

• Adult:
PO
50 mg 60-90 min prior to sexual activity

Available forms:
Tabs 20, 25, 50, 100 mg; sol for inj 10 mg/12.5 ml

Administer:

• 
Erectile dysfunction:
give approximately 1 hr before sexual activity; do not use more than 1×/day, give on empty stomach for better absorption

• 
Pulmonary hypertension:
give 3×/day, 4-6 hr apart

SIDE EFFECTS

CNS:
Headache, flushing, dizziness
, transient global amnesia,
seizures

CV:
MI, sudden death, CV collapse, TIAs, ventricular dysrhythmias, CV hemorrhage

MISC.:
Dyspepsia, nasal congestion, UTI, abnormal vision, diarrhea, rash
,
nonarteritic ischemic optic neuropathy,
hearing loss, priapism,
sickle cell crisis

PHARMACOKINETICS

Rapidly absorbed; bioavailability 40%; metabolized by P45 CYP3A4, 2C9 in the liver (active metabolites); terminal half-life 4 hr; peak 15-30 min; reduced absorption with high-fat meal; excreted in feces, urine

INTERACTIONS

 
Do not use with nitrates; fatal fall in B/P

Increase:
sildenafil levels—cimetidine, erythromycin, ketoconazole, itraconazole, antiretroviral protease inhibitors, tacrolimus

Decrease:
sildenafil levels—CYP-450 inducers, rifampin, barbiturates, bosentan, carBAMazepine, dexamethasone, phenytoin, nevirapine, rifabutin, troglitazone; antacids

Decrease:
B/P—α-blockers, alcohol, amlodipine, angiotensin II receptor blockers

Drug/Food

Increase:
product effect—grapefruit

Decrease:
absorption—high-fat meal

NURSING CONSIDERATIONS
Assess:

• 
Phosphodiesterase type 5 inhibitors with lopinavir/ritonavir (Kaletra):
assess for hypotension, visual changes, prolonged erection, syncope; give only 25 mg q48hr and monitor for adverse reactions

• 
Erectile dysfunction prior to use

 
Any severe loss of vision while taking this or any similar products; products should not be used

 
Use of organic nitrates that should not be used with this product

• 
MI, sudden death, CV collapse:
those with an MI within 6 mo, resting hypotension <90/50, resting hypertension >170/100, fluid depletion should use this product cautiously; may occur right after sexual activity to days afterward

• 
Sickle cell crisis (vasoocclusive crisis):
when used for pulmonary hypertension, may require hospitalization

• 
Cardiac status, hemodynamic parameters, exercise tolerance in pulmonary hypertension: B/P, pulse

Evaluate:

• 
Therapeutic response: decreasing pulmonary hypertension/improved exercise tolerance; ability to perform sexually (male)

Teach patient/family:

• 
That product does not protect against sexually transmitted diseases, including HIV

• 
That product absorption is reduced with a high-fat meal

• 
That product should not be used with nitrates in any form

• 
That tabs may be split

 
To notify prescriber immediately and to stop taking product if vision/hearing loss occurs or erection lasts >4 hr

• 
That erections lasting >4 hr may occur, report to prescriber immediately

• 
Do not use more than 100 mg in 24 hr

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

silodosin (Rx)

(si-lo′do-seen)

Rapaflo

Func. class.:
Selective α
1
-adrenergic blocker, BPH agent

Chem. class.:
Sulfamoylphenethylamine derivative

ACTION:

Binds preferentially to α
1A
-adrenoceptor subtype located mainly in the prostate

USES:

Symptoms of benign prostatic hyperplasia (BPH)

CONTRAINDICATIONS:

Hypersensitivity, renal failure, hepatic disease

Precautions:
Pregnancy (B), breastfeeding, children, females, geriatric patients, renal/hepatic disease, hypotension, ocular surgery, orthostatic hypotension, prostate cancer, syncope

DOSAGE AND ROUTES
Calculator

• Adult:
PO
8 mg/day with meal; max 8 mg/day

Renal dose

• Adult:
PO
CCr 30-49 ml/min, 4 mg/day; CCr <30 ml/min, not recommended

Available forms:
Cap 4, 8 mg

Administer:

• 
Give with meal at same time each day

• 
Cap may be opened and sprinkled in applesauce

SIDE EFFECTS

CNS:
Dizziness, headache
, asthenia, insomnia, syncope

CV:
Orthostatic hypotension

EENT:
Nasal congestion, rhinorrhea, sinusitis

GI:
Diarrhea, abdominal pain, jaundice

GU:
Abnormal ejaculation, priapism, urinary incontinence

HEMA:
Purpura

PHARMACOKINETICS

Decreased absorption with high-fat/high-calorie meal, half-life of metabolite 24 hr, metabolized in liver, excreted via urine, extensively protein bound (97%)

INTERACTIONS

Increase:
silodosin effect—CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir, antiretroviral protease inhibitors, aprepitant, chloramphenicol, conivaptan, dalfopristin, danazol, delavirdine, efavirenz, fosaprepitant, fluconazole, fluvoxaMINE, imatinib, isoniazid, mifepristone, nefazodone, tamoxifen, telithromycin, troleandomycin, voriconazole, zileuton, zafirlukast)

Drug/Food

Increase:
silodosin effect—grapefruit juice

Drug Lab/Test

Increase:
LFTs

NURSING CONSIDERATIONS
Assess:

• 
Prostatic hyperplasia:
change in urinary patterns at baseline and through
out treatment, testing for prostate cancer, before administration is recommended

• 
BUN, uric acid, urodynamic studies (urinary flow rates, residual volume)

• 
I&O ratios, weight daily; edema, report weight gain or edema

• 
B/P, monitor for orthostatic hypotension

Perform/provide:

• 
Storage at room temp; protect from light and moisture

Evaluate:

• 
Therapeutic response: decreased symptoms of BPH

Teach patient/family

• 
Not to drive, operate machinery until effect known

• 
Not to use with grapefruit juice

• 
To take with same meal each day

Other books

Erased by Marshall, Jordan
The Snake Stone by Jason Goodwin
Going Dark (Nightfallen #1) by S.G. Schvercraft
Poison by Chris Wooding
Never to Sleep by Rachel Vincent
Carpool Confidential by Jessica Benson